MX365957B - Métodos y composiciones para vacunas del virus del dengue. - Google Patents

Métodos y composiciones para vacunas del virus del dengue.

Info

Publication number
MX365957B
MX365957B MX2016000235A MX2016000235A MX365957B MX 365957 B MX365957 B MX 365957B MX 2016000235 A MX2016000235 A MX 2016000235A MX 2016000235 A MX2016000235 A MX 2016000235A MX 365957 B MX365957 B MX 365957B
Authority
MX
Mexico
Prior art keywords
dengue virus
methods
compositions
virus vaccines
glycoprotein
Prior art date
Application number
MX2016000235A
Other languages
English (en)
Other versions
MX2016000235A (es
Inventor
Messer William
Baric Ralph
DESILVA Aravinda
Yount Boyd
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2016000235A publication Critical patent/MX2016000235A/es
Publication of MX365957B publication Critical patent/MX365957B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a composiciones y métodos de uso que comprenden una glucoproteína E quimérica del virus del dengue que comprende una estructura de base de glucoproteína E del virus del dengue, la cual comprende sustituciones de aminoácido que introducen un epítopo que es reconocido por un anticuerpo de un serotipo del virus del dengue que es diferente del serotipo de virus del dengue de la estructura de base de glucoproteína E del virus del dengue.
MX2016000235A 2013-06-26 2014-06-26 Métodos y composiciones para vacunas del virus del dengue. MX365957B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839687P 2013-06-26 2013-06-26
PCT/US2014/044410 WO2014210358A1 (en) 2013-06-26 2014-06-26 Methods and compositions for dengue virus vaccines

Publications (2)

Publication Number Publication Date
MX2016000235A MX2016000235A (es) 2016-08-11
MX365957B true MX365957B (es) 2019-06-20

Family

ID=52142690

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000235A MX365957B (es) 2013-06-26 2014-06-26 Métodos y composiciones para vacunas del virus del dengue.
MX2019007252A MX2019007252A (es) 2013-06-26 2016-01-07 Metodos y composiciones para vacunas del virus del dengue.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019007252A MX2019007252A (es) 2013-06-26 2016-01-07 Metodos y composiciones para vacunas del virus del dengue.

Country Status (12)

Country Link
US (2) US10053493B2 (es)
EP (2) EP3590955A1 (es)
JP (2) JP6525984B2 (es)
KR (1) KR20160027019A (es)
CN (2) CN110734500A (es)
AU (2) AU2014302282B2 (es)
BR (1) BR112015032388A8 (es)
CA (1) CA2918644A1 (es)
ES (1) ES2745431T3 (es)
MX (2) MX365957B (es)
SG (1) SG11201510617WA (es)
WO (1) WO2014210358A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398768B2 (en) 2014-11-02 2019-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
TWI769185B (zh) 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
US11241491B2 (en) 2017-05-23 2022-02-08 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus serotype 4 epitopes
WO2018231974A1 (en) * 2017-06-14 2018-12-20 Thomas Jefferson University Composition and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies
WO2023056335A1 (en) * 2021-09-30 2023-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
CA2576798C (en) 2004-07-27 2014-09-09 Gwong-Jen J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
AU2005295438B2 (en) * 2004-10-20 2012-07-05 Sanofi Pasteur Biologics, Llc Vaccines against Japanese encephalitis virus and West Nile virus
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
BR112012024224A2 (pt) * 2010-03-24 2016-11-29 Arbovax Inc mutações da faixa de hospedeiro de flavivírus e seu uso.
CN102906266A (zh) * 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
WO2012027473A2 (en) 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
EA201390874A1 (ru) * 2010-12-14 2013-12-30 Нэшнл Юниверсити Оф Сингапур Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
EP3269728B1 (en) 2011-10-20 2020-12-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
WO2013151764A1 (en) 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes

Also Published As

Publication number Publication date
ES2745431T3 (es) 2020-03-02
JP2019195328A (ja) 2019-11-14
AU2014302282A1 (en) 2016-02-11
AU2018278927A1 (en) 2019-01-17
CN105473603A (zh) 2016-04-06
JP2016523912A (ja) 2016-08-12
US10053493B2 (en) 2018-08-21
BR112015032388A2 (pt) 2017-07-25
EP3590955A1 (en) 2020-01-08
KR20160027019A (ko) 2016-03-09
CN105473603B (zh) 2019-10-25
CN110734500A (zh) 2020-01-31
JP6525984B2 (ja) 2019-06-05
BR112015032388A8 (pt) 2020-01-14
MX2016000235A (es) 2016-08-11
EP3013852A1 (en) 2016-05-04
CA2918644A1 (en) 2014-12-31
US20190225654A1 (en) 2019-07-25
US10870682B2 (en) 2020-12-22
EP3013852B1 (en) 2019-06-19
AU2014302282B2 (en) 2018-09-13
MX2019007252A (es) 2019-08-16
US20160257719A1 (en) 2016-09-08
SG11201510617WA (en) 2016-01-28
WO2014210358A1 (en) 2014-12-31
EP3013852A4 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
IL287718A (en) Chimeric antigen receptors (cars), preparations and methods for their use
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
CY1121560T1 (el) Ανοσογονικη συνθεση
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
EP3237439A4 (en) Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2023006416A (es) Anticuerpos, usos y metodos.
PH12016501366A1 (en) Novel anti-baff antibodies
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
IN2014MU01248A (es)
MX2019005102A (es) Poxvirus quimericos sinteticos.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
WO2014145245A3 (en) Methods and compositions for norovirus blockade epitopes
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2019007924A (es) Vacunas contra la influenza.
EA201691203A1 (ru) Твёрдые формы тенофовира
WO2014188212A3 (en) Treatment and prevention of malaria

Legal Events

Date Code Title Description
FG Grant or registration